NASDAQ:MNKD MannKind (MNKD) Stock Price, News & Analysis → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Free MNKD Stock Alerts $4.18 -0.01 (-0.24%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$4.12▼$4.2450-Day Range$3.55▼$5.2752-Week Range$3.17▼$5.75Volume1.78 million shsAverage Volume2.95 million shsMarket Capitalization$1.13 billionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get MannKind alerts: Email Address MannKind MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside91.4% Upside$8.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings Growth77.78%From $0.09 to $0.16 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.66 out of 5 starsMedical Sector642nd out of 907 stocksPharmaceutical Preparations Industry289th out of 422 stocks 3.5 Analyst's Opinion Consensus RatingMannKind has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMannKind has only been the subject of 2 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for MNKD. Previous Next 0.0 Dividend Strength Dividend YieldMannKind does not currently pay a dividend.Dividend GrowthMannKind does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MNKD. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 3 people have searched for MNKD on MarketBeat in the last 30 days. This is a decrease of -90% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added MannKind to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MannKind insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.00% of the stock of MannKind is held by insiders.Percentage Held by Institutions49.55% of the stock of MannKind is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for MannKind are expected to grow by 77.78% in the coming year, from $0.09 to $0.16 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MannKind is -83.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MannKind is -83.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. About MannKind Stock (NASDAQ:MNKD)MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.Read More MNKD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MNKD Stock News HeadlinesApril 16, 2024 | americanbankingnews.comMannKind (NASDAQ:MNKD) Share Price Crosses Above 200 Day Moving Average of $3.90April 3, 2024 | globenewswire.comMannKind Repays Certain Debt ObligationsApril 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.April 1, 2024 | finance.yahoo.comMannKind Corporation (NASDAQ:MNKD) down to US$1.2b market cap, but institutional owners may not be as affected after a year of 9.7% returnsMarch 30, 2024 | nasdaq.comMay 10th Options Now Available For MannKind (MNKD)March 28, 2024 | uk.investing.comMannKind CFO Steven Binder to retire, Chris Prentiss to take overMarch 26, 2024 | globenewswire.comMannKind Announces CFO TransitionMarch 25, 2024 | finance.yahoo.comJim Cramer Says You Should Avoid These 11 StocksApril 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.March 17, 2024 | finance.yahoo.comMNKD Mar 2024 5.000 putMarch 16, 2024 | finance.yahoo.comMNKD Mar 2024 4.000 callMarch 16, 2024 | finance.yahoo.comMNKD Mar 2024 4.500 putMarch 11, 2024 | msn.comWhat's Going On With MannKind Stock?March 11, 2024 | finance.yahoo.comINHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin PumpsMarch 11, 2024 | globenewswire.comINHALE-3 Study's Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin PumpsMarch 10, 2024 | finance.yahoo.comMNKD Mar 2024 6.500 callMarch 9, 2024 | finance.yahoo.comMNKD Mar 2024 3.000 putMarch 8, 2024 | finance.yahoo.comMNKD Mar 2024 3.500 putMarch 5, 2024 | globenewswire.comMannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8March 4, 2024 | globenewswire.comMannKind Corporation Announces Participation at Upcoming ConferencesMarch 3, 2024 | ca.finance.yahoo.comMNKD Mar 2024 7.000 callMarch 3, 2024 | finance.yahoo.comAnalysts Just Made A Meaningful Upgrade To Their MannKind Corporation (NASDAQ:MNKD) ForecastsFebruary 29, 2024 | finance.yahoo.comMannKind Full Year 2023 Earnings: Beats ExpectationsFebruary 29, 2024 | uk.finance.yahoo.comMannKind Corporation (MNKD) stock price, news, quote & history – Yahoo FinanceFebruary 28, 2024 | markets.businessinsider.comMannKind Corporation: Strong Growth and Clinical Advancements Prompt Buy RatingFebruary 28, 2024 | finance.yahoo.comMannKind Corporation (NASDAQ:MNKD) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | finance.yahoo.comQ4 2023 MannKind Corp Earnings CallSee More Headlines Receive MNKD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MannKind and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today4/25/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:MNKD CUSIP56400P20 CIK899460 Webwww.mannkindcorp.com Phone(818) 661-5000Fax661-775-2081Employees411Year Founded1991Price Target and Rating Average Stock Price Target$8.00 High Stock Price Target$10.00 Low Stock Price Target$6.50 Potential Upside/Downside+93.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.05) Trailing P/E RatioN/A Forward P/E Ratio46.00 P/E GrowthN/ANet Income$-11,940,000.00 Net Margins-6.00% Pretax Margin-5.22% Return on EquityN/A Return on Assets-3.62% Debt Debt-to-Equity RatioN/A Current Ratio3.59 Quick Ratio3.31 Sales & Book Value Annual Sales$198.96 million Price / Sales5.63 Cash FlowN/A Price / Cash FlowN/A Book Value($0.91) per share Price / Book-4.55Miscellaneous Outstanding Shares270,680,000Free Float262,559,000Market Cap$1.12 billion OptionableOptionable Beta1.28 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Michael E. Castagna Pharm.D. (Age 47)CEO & Director Comp: $1.26MMr. Steven B. Binder (Age 61)Chief Financial Officer Comp: $800.2kDr. David B. Thomson J.D. (Age 57)Ph.D., Executive VP, General Counsel & Secretary Comp: $798.53kDr. Stuart A. Tross Ph.D. (Age 57)Executive VP and Chief People & Workplace Officer Comp: $678.4kMr. Sanjay Singh M.B.A. (Age 58)Executive Vice President of Technical Operations Comp: $364.53kMs. Lauren M. Sabella (Age 63)Executive VP & COO Ms. Rosabel Realica Alinaya (Age 63)VP of Investor Relations & Treasury Comp: $402.26kMr. John F. Bedard (Age 74)Senior Vice President of Worldwide Regulatory Affairs Mr. James Patrick McCauley Jr. (Age 58)J.D., M.B.A., Chief Commercial Officer Comp: $614.06kDr. Burkhard Blank M.D. (Age 69)Executive VP of Research & Development and Chief Medical Officer More ExecutivesKey CompetitorsLigand PharmaceuticalsNASDAQ:LGNDInnovivaNASDAQ:INVAIronwood PharmaceuticalsNASDAQ:IRWDOPKO HealthNASDAQ:OPKDynavax TechnologiesNASDAQ:DVAXView All CompetitorsInsiders & InstitutionsSimplex Trading LLCBought 292,400 shares on 4/25/2024Ownership: 0.000%Hennion & Walsh Asset Management Inc.Bought 98,282 shares on 4/17/2024Ownership: 0.087%180 Wealth Advisors LLCBought 216,880 shares on 4/16/2024Ownership: 0.718%Virtu Financial LLCBought 44,737 shares on 2/26/2024Ownership: 0.036%Parkman Healthcare Partners LLCBought 429,677 shares on 2/15/2024Ownership: 0.927%View All Insider TransactionsView All Institutional Transactions MNKD Stock Analysis - Frequently Asked Questions Should I buy or sell MannKind stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MannKind in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MNKD shares. View MNKD analyst ratings or view top-rated stocks. What is MannKind's stock price target for 2024? 3 analysts have issued 1-year target prices for MannKind's stock. Their MNKD share price targets range from $6.50 to $10.00. On average, they anticipate the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 91.4% from the stock's current price. View analysts price targets for MNKD or view top-rated stocks among Wall Street analysts. How have MNKD shares performed in 2024? MannKind's stock was trading at $3.64 on January 1st, 2024. Since then, MNKD shares have increased by 14.8% and is now trading at $4.18. View the best growth stocks for 2024 here. When is MannKind's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our MNKD earnings forecast. How were MannKind's earnings last quarter? MannKind Co. (NASDAQ:MNKD) released its quarterly earnings data on Tuesday, February, 27th. The biopharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.01) by $0.02. The biopharmaceutical company earned $58.47 million during the quarter, compared to the consensus estimate of $52.36 million. What ETFs hold MannKind's stock? ETFs with the largest weight of MannKind (NASDAQ:MNKD) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE) and Invesco Nasdaq Future Gen 200 ETF (QQQS).iShares Micro-Cap ETF (IWC). What other stocks do shareholders of MannKind own? Based on aggregate information from My MarketBeat watchlists, some companies that other MannKind investors own include Bausch Health Companies (BHC), Novavax (NVAX), Geron (GERN), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD), Chesapeake Energy (CHKAQ), Micron Technology (MU), NVIDIA (NVDA), Intel (INTC) and Gilead Sciences (GILD). Who are MannKind's major shareholders? MannKind's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include 180 Wealth Advisors LLC (0.72%), Simplex Trading LLC (0.00%) and Hennion & Walsh Asset Management Inc. (0.09%). Insiders that own company stock include Alejandro Galindo, Anthony C Hooper, David Thomson, Michael Castagna, Steven B Binder, Stuart A Tross and Stuart A Tross. View institutional ownership trends. How do I buy shares of MannKind? Shares of MNKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MNKD) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsYour Money is Not SafeAmerican AlternativeThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MannKind Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.